Rochelle Bagatell Research Program
Ongoing Research
Researchers are assessing the use of an RNA-modified form of chimeric antigen receptor (CAR) T cells to treat refractory and relapsed neuroblastoma.
Inhibition of the TRK tyrosine kinase family has shown enduring response in clinical trials and efforts are underway to assess newer TRK inhibitors.
Researchers are currently enrolling patients for this Phase III trial assessing the addition of the radiopharmaceutical MIBG to standard care for high-risk neuroblastoma.